...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Canadian journal of diabetes >Effects on Diabetes Medications, Weight and Glycated Hemoglobin Among Adult Patients With Obesity and Type 2 Diabetes: 6-Month Observations From a Full Meal Replacement, Low-Calorie Diet Weight Management Program
【24h】

Effects on Diabetes Medications, Weight and Glycated Hemoglobin Among Adult Patients With Obesity and Type 2 Diabetes: 6-Month Observations From a Full Meal Replacement, Low-Calorie Diet Weight Management Program

机译：肥胖患者的糖尿病药物，体重和糖化血红蛋白的影响和2型糖尿病：6个月的全餐更换，低卡路里饮食重量管理计划

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

ObjectivesA 6-month weight-management program with full meal replacement, low-calorie diet (full MR-LCD) (900?kcal/day for 6 to 12 weeks) follows a protocol for patients with diabetes for decreasing or discontinuing weight-gaining diabetes medications first (Group WG) and then titrating weight-neutral medications (Group WN). MethodsThis is a retrospective cohort study (1992 to 2009) of weight, glycemic control and diabetes medications changes in 317 patients with obesity and type 2 diabetes who were taking medications. ResultsGroup WG and Group WN were similar at baseline, except that glycated hemoglobin (A1C) levels were significantly lower in Group WN (7.5% vs. 6.6%; p<0.001). At 6 months, both groups had lost 16% of their weight, and the decreases or discontinuations of medications were 92.1% sulfonureas, 86.5% insulins, 78.8% thiazolidinediones, 77.8% alpha-glucosidase inhibitors, 50% meglitinides, 33.3% dipeptidyl peptidase-4 (DPP-4) inhibitors and 32.8% metformin. At 6 months, compared with baseline, A1C levels improved in Group WG and Group WN (6-month A1C levels 6.7% and 5.8%, respectively; p<0.0001), and Group WN had significantly better A1C levels than Group WG. At 6 months, 30% of patients were no longer taking diabetes medications and had significantly better percentages of weight loss compared with those taking medications (18.6% vs. 16%; p=0.002); both groups had improved glycemic control at 6 months (A1C 6.0% vs. A1C 6.6%; NS). ConclusionsIn patients with obesity and type 2 diabetes taking medications, a full MR-LCD program appears to be safe and includes improvement in A1C levels. At 6 months, the percentage of weight loss can be significantly better in patients who no longer require diabetes medications, and A1C levels are best controlled in patients who are on WN medications.
机译：Objectivesa 6个月的重量管理程序，具有完整的膳食更换，低卡路里饮食（全文MR-LCD）（900？KCAL / DAY 6至12周）遵循糖尿病患者的糖尿病患者，用于减少或停止体重增加糖尿病药物第一（组WG），然后滴定重量中性药物（组WN）。方法是一项回顾性队列研究（1992年至2009年）的体重，血糖控制和糖尿病药物在317例肥胖患者中发生的变化，患有药物的2例糖尿病。结果组WG和组WN在基线中类似，除了血糖血红蛋白（A1C）水平在WN组中显着降低（7.5％vs.6.6％; P <0.001）。在6个月时，两组均失去了16％的体重，药物减少或中断为92.1％磺脲类，86.5％胰岛，78.8％噻唑烷基，77.8％α-葡糖苷酶抑制剂，50％麦格兰糖苷，33.3％二肽基肽酶 - 4（DPP-4）抑制剂和32.8％二甲双胍。在6个月内，与基线相比，WG组和群体（6个月A1C水平分别为6.7％和5.8％）改善A1C水平，分别比WG组显着更好的A1C水平。 6个月，30％的患者不再服用糖尿病药物，与服用药物的药物相比，减肥百分比明显更好（18.6％与16％; p = 0.002）;两组在6个月内改善了血糖控制（A1C 6.0％与A1C 6.6％; NS）。结论肥胖症患者和2型糖尿病服用药物，完整的MR-LCD计划似乎是安全的，包括A1C水平的改善。在6个月，在不再需要糖尿病药物的患者中，重量损失的百分比可以显着更好，并且在WN药物的患者中最好控制A1C水平。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号